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Thirty years before genetic experiments in Drosophila created
the  hedgehog mutant [1], a naturally occurring ‘chemical
genetic’ experiment had produced sheep with an even more
disturbing phenotype: cyclopia. The lack of midline facial
structures in the offspring of grazing sheep in the western
United States was attributed to ingestion of the lily Veratrum
californicum, and subsequent work identified the jervine family
of steroidal alkaloids, including the compound cyclopamine,
as the teratogens responsible for the striking effects [2].
Insights into a possible mechanism of action did not emerge
until the mid 1990s, when it was discovered that mutation of
the Sonic hedgehog (Shh) gene in mice [3] or humans [4] could
produce defects that resembled those caused by administra-
tion of cyclopamine to animals. Shh is a secreted protein
ligand that, like other members of the Hedgehog (Hh) family,
activates the Hh signal transduction pathway, and plays an
important role in patterning many tissues [5]. The similarity in
phenotypes suggested that teratogens might induce cyclopia
by antagonizing the Hh pathway, and this hypothesis was
confirmed when it was found that cyclopamine could directly
block the response of tissues to Shh without interfering with
the generation or processing of the Shh ligand [6,7]. 
How does cyclopamine block the response of cells to Shh?
An exciting answer to this question has just emerged from
the Beachy lab [8], which has identified the target of
cyclopamine as the protein Smoothened (Smo), a protein
with seven transmembrane domains that is distantly related
to G-protein coupled receptors (GPCRs) [5]. In unstimu-
lated cells, the activity of Smo is somehow repressed by the
protein Patched (Ptc), which appears to be the receptor for
the Shh ligand. When Ptc is engaged by Shh, Smo is acti-
vated and stimulates transcription factors of the Cubitus
interruptus (Ci) or Gli family to induce the expression of
specific genes. How Smo activates these transcription factors
also remains unclear: although Smo has distant homology
to GPCRs, no G protein has yet been identified as essential
for Hh-pathway signaling. 
Like other GPCRs, however, it now appears that Smo can be
activated by small molecules. In this issue of the Journal of
Biology, Jeff Porter and colleagues [9] at Curis Inc. report the
identification of a class of synthetic small molecules (see
Figure 1a) that potently activate the Hh-signaling pathway
by binding to the Smo protein. I will refer to this chemical
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Abstract
Small-molecule antagonists of Hedgehog-pathway signaling, such as cyclopamine, have been
known for some time. Now, small-molecule agonists of the Hedgehog pathway have also been
identified. The finding that both antagonists and agonists target the protein Smoothened supports
the emerging hypothesis that Smoothened may be regulated by endogenous small molecules. 
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meaning smooth), to reflect their ability to target the Smo
protein. In addition to having important therapeutic impli-
cations (see the article by Stecca and Ruiz i Altaba in this
issue [10]), the discovery of leiosamine also supports the
exciting new idea that endogenous small molecules may
regulate Smo activity in vivo [11]. 
The distinct routes by which cyclopamine and leiosamine
were discovered provide an interesting glimpse into the
changing nature of small-molecule discovery in biology and
medicine. Cyclopamine was discovered through a natural
accident, whereas leiosamine was discovered by systematic
screening of chemical libraries using a cell-based assay that
monitored Hh-pathway activation. The goal of screening
against an entire pathway, rather than taking a more tar-
geted approach, is to let the pathway reveal which compo-
nents are most sensitive to pharmacological perturbation.
Because this type of broad phenotypic screening emulates
traditional genetics it has been referred to as “chemical
genetics” [12-14]. The approach is ambitious and not
without risk, because real biological insight (and perhaps
approval by the US Food and Drug Administration of any
resulting drug) requires identification of the target protein.
The challenging nature of target identification is a key reason
that many drug companies stick to screening isolated target
proteins. But the recent success in identifying Smo as the
target of cyclopamine and leiosamine suggests that the chal-
lenge of target identification can be overcome, and that
pathway-based screening strategies can yield valuable divi-
dends. In the remainder of this article, I will summarize how
the Smo protein was identified as a receptor for small mole-
cules, and the implications of this finding for understanding
the mechanism of Hh signal transduction. 
The target of cyclopamine was not discovered blindly;
instead, several clues pointed to Smo as a possible target.
The Beachy group had previously shown that cyclopamine
remained competent to block Hh signaling even in cell lines
in which signaling was constitutively activated by loss-of-
function mutations in Ptc, placing the site of cyclopamine
action downstream of Ptc [15]. Cyclopamine could also
block signaling by constitutively activated oncogenic
mutant forms of Smo, although higher concentrations were
required, highlighting the possibility that Smo might be a
target. To test this hypothesis, Chen et al. [8] synthesized a
radiolabeled version of cyclopamine containing a photo-
activatable crosslinker. Transfection of cells with a tagged
version of Smo allowed detection of specific crosslinking to
Smo that could be specifically competed by unlabeled
cyclopamine. Cells transfected with Smo were also shown to
bind specifically to a fluorescent derivative of cyclopamine,
and by expressing truncation mutants of Smo, Chen et al.
showed that cyclopamine binding requires only the seven
transmembrane-spanning domains of Smo. Taken together,
these findings strongly suggest that cyclopamine inhibits
Hh signal transduction by binding to Smo. 
The Curis group was interested in identifying small mole-
cules that could activate the Hh pathway in the absence of
the Shh ligand. Frank-Kamenetsky et al. [9] first established
a mouse cell line that upregulated luciferase expression in
response to addition of Shh protein. Screening of 140,000
compounds for the ability to activate luciferase expression
in the absence of Shh protein led to the identification of the
leiosamine family of compounds. Medicinal chemistry
efforts improved the potency of this class of compounds by
a thousand-fold, with significant enhancement of activity
after alkylation of a basic nitrogen. The authors demon-
strated that leiosamine is capable of stimulating the expres-
sion of Hh-specific genes in cells and also of activating
appropriate Hh-dependent biological responses, such as
proliferation of neonatal cerebellar granule neurons. In an
assay using an explant of the developing chick neural plate,
leiosamine was shown to induce dose-dependent changes
in cell fate, as would be expected for a Hh-pathway agonist.
Even more excitingly, one leiosamine derivative was able to
activate Ptc expression (a target of Hh-pathway activation)
in mouse embryos after oral administration to pregnant
females [9]. In an elegant set of experiments, the Curis
group took advantage of this activity of leiosamine in vivo to
narrow the range of possible targets. Mouse embryos with
homozygous mutations in the Shh gene normally fail to
express Hh-pathway target genes such as Ptc. Treatment of
pregnant mothers carrying Shh-/- embryos with leiosamine
was shown to restore Ptc expression, indicating that
leiosamine can activate the Hh pathway in the absence of
Shh ligand. Signaling was not restored in Smo-/- embryos,
however, indicating that Smo is essential for the signaling
that is activated by leiosamine.
Additional experiments in cell culture also hinted that Smo
might be a target of leiosamine. Forskolin, a downstream
inhibitor of the Hh pathway, was found to inhibit
leiosamine-stimulated signaling as well as signaling acti-
vated by addition of Shh protein. But cyclopamine inhib-
ited leiosamine-stimulated signaling less than it inhibited
Shh-driven signaling, suggesting that cyclopamine and
leiosamine might target the same receptor. To test the
hypothesis that Smo is the biochemical target of leiosamine,
the authors prepared a tritiated version of leiosamine and
used it to treat cells that overexpressed an epitope-tagged
version of Smo. The authors were able to immunoprecipi-
tate a substantial fraction of the input radioactive counts
only in cell lines in which Smo was overexpressed, and this
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leiosamine or cyclopamine. Another novel antagonist of the
Hh pathway, Cur61414 ([16]; Figure 1b), was also found to
compete with leiosamine for binding, suggesting that it also
targets Smo. Equilibrium binding measurements using
membranes containing Smo protein indicated that the best
leiosamine derivative bound to wild-type Smo with a disso-
ciation constant (Kd) of 0.37 nM. Interestingly, when this
experiment was repeated using membranes containing the
activated mutant of Smo, the strength of leiosamine binding
was not affected, whereas binding of antagonists was sub-
stantially weakened. To explain this observation, the
authors propose that leiosamine and cyclopamine bind to
separate sites on Smo, but that negative cooperativity
between the sites results in antagonistic binding. 
The Beachy lab has also recently characterized leiosamine
and has confirmed the Smo protein as its target using
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Figure 1
The structures of small molecules that activate or inhibit Hedgehog (Hh) signaling. (a) The leiosamine family of compounds that activate Hh signaling
by binding to Smoothened. Hh-Ag (Hedgehog agonist) 1.1 was the original compound identified in the high-throughput screen by Frank-Kamenetsky
et al. [9], with an EC50 of 3 M in their luciferase reporter assay. Hh-Ag 1.2 is a more potent derivative that is also characterized by Chen et al. [17],
who refer to it as SAG for ‘synthetic Hh agonist’. Hh-Ag 1.5 is the most potent Hh agonist reported [9], with an EC50 of 1 nM. (b) The structures of
two compounds that bind to Smoothened to inhibit Hh signaling, cyclopamine and Cur61414. Structurally distinct classes of Smoothened antagonists
have also been reported [17] but are not shown here. 
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Ophoto-affinity crosslinking experiments with a radiolabeled
version of leiosamine [17]. Competition experiments with
fluorescently labeled cyclopamine suggest that the trans-
membrane heptahelical bundle of Smo is sufficient for
leiosamine binding. Interestingly, higher concentrations of
leiosamine are inhibitory to Hh signaling, suggesting that
the compound may also interact with a downstream effector
protein that becomes titrated away from Smo at high con-
centrations of ligand. The identity of this effector is
unknown, but perhaps leiosamine will be a useful tool in
its identification.
The susceptibility of Smo to activation or inhibition by syn-
thetic small molecules suggests the intriguing possibility that
endogenous small molecules may also regulate Smo activity.
But how does this idea fit with current thinking about Hh-
pathway signal transduction? Early models proposed that Ptc
might regulate Smo by forming a stoichiometric complex.
But recent work indicates that Ptc can inhibit Smo at sub-
stoichiometric levels [11]. Ptc has homology to a family of
bacterial transmembrane proteins that can transport small
molecules, and inactivating mutations in Ptc are similar to
those known to abolish transport activity in bacteria. It has
therefore been proposed that Ptc may transport a small mol-
ecule that binds Smo and regulates its activity [11]. Now that
we know that Smo can be either activated or inhibited by
synthetic small molecules, the discovery of the natural
endogenous counterparts is eagerly anticipated. 
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